Matches in SemOpenAlex for { <https://semopenalex.org/work/W3112805961> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W3112805961 endingPage "S426" @default.
- W3112805961 startingPage "S426" @default.
- W3112805961 abstract "Time to next treatment (TNT) may be a patient-relevant endpoint by capturing durable response, post-progression benefit, and the time free of systemic anticancer therapy, which may be achieved with immune-checkpoint inhibitors (ICI). This study investigated TNT as a surrogate endpoint (SE) of overall survival (OS) in previously untreated advanced melanoma patients. Patient-level data from the 60-month results of the CheckMate-067 randomized clinical trial (RCT) (NCT01844505) were used. Analyses were performed for nivolumab monotherapy (NIVO) or nivolumab with ipilimumab (NIVO+IPI) versus ipilimumab monotherapy (IPI). The SE one-step validation method based on a joint frailty model was used where the country of residence was applied to define synthetic clusters. Kendall’s τ and the coefficient of determination (R2trial) were estimated for respective measurements of association at the individual and cluster levels. Surrogate threshold effect (STE), the maximum threshold hazard ratio (HR) for TNT that would translate into OS benefit, was estimated. A leave-one-out cross-validation analysis was performed to evaluate model robustness and predictive accuracy. Fifteen clusters were considered from 945 patients. For both nivolumab-containing arms, the association between TNT and OS was deemed acceptable at the individual level (Kendall’s τ >0.60) and strong at the cluster level, with R2trial fairly close to 1, and narrow confidence intervals. The estimated STEs were 0.58 for NIVO versus IPI and 0.39 for NIVO+IPI versus IPI. Cross-validation results showed minimum variation of the correlation measures and modest predictive accuracy for the model. The observed and predicted HRs of OS were closer to each other in the comparison of NIVO+IPI versus IPI than with NIVO versus IPI. Results suggest that TNT may be a valuable SE in previously untreated advanced melanoma patients treated with ICI. Surrogacy analyses considering multiple RCTs of ICI-treated melanoma patients are warranted for confirming these findings and for improving the accuracy of the predictions." @default.
- W3112805961 created "2020-12-21" @default.
- W3112805961 creator A5009168027 @default.
- W3112805961 creator A5035035805 @default.
- W3112805961 creator A5035574764 @default.
- W3112805961 creator A5050773185 @default.
- W3112805961 creator A5051682700 @default.
- W3112805961 creator A5051870782 @default.
- W3112805961 creator A5060949051 @default.
- W3112805961 creator A5080756848 @default.
- W3112805961 date "2020-12-01" @default.
- W3112805961 modified "2023-09-27" @default.
- W3112805961 title "PCN29 Time to Next Treatment As a Candidate Surrogate Endpoint for Overall Survival in Previously Untreated Advanced Melanoma Patients Treated with Immune-Checkpoint Inhibitors" @default.
- W3112805961 doi "https://doi.org/10.1016/j.jval.2020.08.166" @default.
- W3112805961 hasPublicationYear "2020" @default.
- W3112805961 type Work @default.
- W3112805961 sameAs 3112805961 @default.
- W3112805961 citedByCount "0" @default.
- W3112805961 crossrefType "journal-article" @default.
- W3112805961 hasAuthorship W3112805961A5009168027 @default.
- W3112805961 hasAuthorship W3112805961A5035035805 @default.
- W3112805961 hasAuthorship W3112805961A5035574764 @default.
- W3112805961 hasAuthorship W3112805961A5050773185 @default.
- W3112805961 hasAuthorship W3112805961A5051682700 @default.
- W3112805961 hasAuthorship W3112805961A5051870782 @default.
- W3112805961 hasAuthorship W3112805961A5060949051 @default.
- W3112805961 hasAuthorship W3112805961A5080756848 @default.
- W3112805961 hasBestOaLocation W31128059611 @default.
- W3112805961 hasConcept C121608353 @default.
- W3112805961 hasConcept C126322002 @default.
- W3112805961 hasConcept C141341695 @default.
- W3112805961 hasConcept C143998085 @default.
- W3112805961 hasConcept C168563851 @default.
- W3112805961 hasConcept C203092338 @default.
- W3112805961 hasConcept C207103383 @default.
- W3112805961 hasConcept C2777658100 @default.
- W3112805961 hasConcept C2777701055 @default.
- W3112805961 hasConcept C2780030458 @default.
- W3112805961 hasConcept C2781433595 @default.
- W3112805961 hasConcept C44249647 @default.
- W3112805961 hasConcept C502942594 @default.
- W3112805961 hasConcept C50382708 @default.
- W3112805961 hasConcept C71924100 @default.
- W3112805961 hasConceptScore W3112805961C121608353 @default.
- W3112805961 hasConceptScore W3112805961C126322002 @default.
- W3112805961 hasConceptScore W3112805961C141341695 @default.
- W3112805961 hasConceptScore W3112805961C143998085 @default.
- W3112805961 hasConceptScore W3112805961C168563851 @default.
- W3112805961 hasConceptScore W3112805961C203092338 @default.
- W3112805961 hasConceptScore W3112805961C207103383 @default.
- W3112805961 hasConceptScore W3112805961C2777658100 @default.
- W3112805961 hasConceptScore W3112805961C2777701055 @default.
- W3112805961 hasConceptScore W3112805961C2780030458 @default.
- W3112805961 hasConceptScore W3112805961C2781433595 @default.
- W3112805961 hasConceptScore W3112805961C44249647 @default.
- W3112805961 hasConceptScore W3112805961C502942594 @default.
- W3112805961 hasConceptScore W3112805961C50382708 @default.
- W3112805961 hasConceptScore W3112805961C71924100 @default.
- W3112805961 hasLocation W31128059611 @default.
- W3112805961 hasOpenAccess W3112805961 @default.
- W3112805961 hasPrimaryLocation W31128059611 @default.
- W3112805961 hasRelatedWork W1794730248 @default.
- W3112805961 hasRelatedWork W2343768426 @default.
- W3112805961 hasRelatedWork W2885885878 @default.
- W3112805961 hasRelatedWork W2904759734 @default.
- W3112805961 hasRelatedWork W2936810997 @default.
- W3112805961 hasRelatedWork W2947482799 @default.
- W3112805961 hasRelatedWork W3084353392 @default.
- W3112805961 hasRelatedWork W3210028029 @default.
- W3112805961 hasRelatedWork W4200337522 @default.
- W3112805961 hasRelatedWork W4285492859 @default.
- W3112805961 hasVolume "23" @default.
- W3112805961 isParatext "false" @default.
- W3112805961 isRetracted "false" @default.
- W3112805961 magId "3112805961" @default.
- W3112805961 workType "article" @default.